Improved survival of HER2+ breast cancer patients treated with trastuzumab and chemotherapy is associated with host antibody immunity against the HER2 intracellular domain

The addition of trastuzumab to chemotherapy extends survival among patients with HER2(+) breast cancer. Prior work showed that trastuzumab and chemotherapy augments HER2 extracellular domain (ECD)-specific antibodies. The present study investigated whether combination therapy induced immune response...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cancer Res
Main Authors: Knutson, Keith L., Clynes, Raphael, Shreeder, Barath, Yeramian, Patrick, Kemp, Kathleen P., Ballman, Karla, Tenner, Kathleen S., Erskine, Courtney L., Norton, Nadine, Northfelt, Donald, Tan, Winston, Calfa, Carmen, Pegram, Mark, Mittendorf, Elizabeth A., Perez, Edith A.
Formato: Artigo
Idioma:Inglês
Publicado em: 2016
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5594563/
https://ncbi.nlm.nih.gov/pubmed/27197192
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/0008-5472.CAN-15-3091
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados